RapamycinFungusV1, Main, Exploration, bibRecord, 000245

Repurposing dasatinib for diffuse large B cell lymphoma.

Identifieur interne : 000245 ( Main/Exploration ); précédent : 000244; suivant : 000246

Repurposing dasatinib for diffuse large B cell lymphoma.

Auteurs : Claudio Scuoppo [États-Unis] ; Jiguang Wang [États-Unis] ; Mirjana Persaud [États-Unis] ; Sandeep K. Mittan [États-Unis] ; Katia Basso [États-Unis] ; Laura Pasqualucci [États-Unis] ; Raul Rabadan [États-Unis] ; Giorgio Inghirami [États-Unis] ; Carla Grandori [États-Unis] ; Francesc Bosch [États-Unis, Espagne] ; Riccardo Dalla-Favera [États-Unis]

Source :

Proceedings of the National Academy of Sciences of the United States of America [ 1091-6490 ] ; 2019.

RBID : pubmed:31383760

Descripteurs français

KwdFr :
- Animaux (MeSH), Complexe-2 cible mécanistique de la rapamycine (métabolisme), Dasatinib (pharmacologie), Humains (MeSH), Lignée cellulaire tumorale (MeSH), Lymphome B diffus à grandes cellules (anatomopathologie), Lymphome B diffus à grandes cellules (métabolisme), Lymphome B diffus à grandes cellules (traitement médicamenteux), Phosphatidylinositol 3-kinases (métabolisme), Phosphohydrolase PTEN (métabolisme), Pyrazoles (pharmacologie), Pyrimidines (pharmacologie), Résistance aux médicaments antinéoplasiques (effets des médicaments et des substances chimiques), Souris (MeSH), Tests d'activité antitumorale sur modèle de xénogreffe (MeSH), Étude de validation de principe (MeSH).
MESH :
- anatomopathologie : Lymphome B diffus à grandes cellules.
- effets des médicaments et des substances chimiques : Résistance aux médicaments antinéoplasiques.
- métabolisme : Complexe-2 cible mécanistique de la rapamycine, Lymphome B diffus à grandes cellules, Phosphatidylinositol 3-kinases, Phosphohydrolase PTEN.
- pharmacologie : Dasatinib, Pyrazoles, Pyrimidines.
- traitement médicamenteux : Lymphome B diffus à grandes cellules.
- Animaux, Humains, Lignée cellulaire tumorale, Souris, Tests d'activité antitumorale sur modèle de xénogreffe, Étude de validation de principe.

English descriptors

KwdEn :
- Animals (MeSH), Cell Line, Tumor (MeSH), Dasatinib (pharmacology), Drug Resistance, Neoplasm (drug effects), Humans (MeSH), Lymphoma, Large B-Cell, Diffuse (drug therapy), Lymphoma, Large B-Cell, Diffuse (metabolism), Lymphoma, Large B-Cell, Diffuse (pathology), Mechanistic Target of Rapamycin Complex 2 (metabolism), Mice (MeSH), PTEN Phosphohydrolase (metabolism), Phosphatidylinositol 3-Kinases (metabolism), Proof of Concept Study (MeSH), Pyrazoles (pharmacology), Pyrimidines (pharmacology), Xenograft Model Antitumor Assays (MeSH).
MESH :
- chemical , metabolism : Mechanistic Target of Rapamycin Complex 2, PTEN Phosphohydrolase.
- chemical , pharmacology : Dasatinib, Pyrazoles, Pyrimidines.
- drug effects : Drug Resistance, Neoplasm.
- drug therapy : Lymphoma, Large B-Cell, Diffuse.
- metabolism : Lymphoma, Large B-Cell, Diffuse, Phosphatidylinositol 3-Kinases.
- pathology : Lymphoma, Large B-Cell, Diffuse.
- Animals, Cell Line, Tumor, Humans, Mice, Proof of Concept Study, Xenograft Model Antitumor Assays.

Abstract

To repurpose compounds for diffuse large B cell lymphoma (DLBCL), we screened a library of drugs and other targeted compounds approved by the US Food and Drug Administration on 9 cell lines and validated the results on a panel of 32 genetically characterized DLBCL cell lines. Dasatinib, a multikinase inhibitor, was effective against 50% of DLBCL cell lines, as well as against in vivo xenografts. Dasatinib was more broadly active than the Bruton kinase inhibitor ibrutinib and overcame ibrutinib resistance. Tumors exhibiting dasatinib resistance were commonly characterized by activation of the PI3K pathway and loss of PTEN expression as a specific biomarker. PI3K suppression by mTORC2 inhibition synergized with dasatinib and abolished resistance in vitro and in vivo. These results provide a proof of concept for the repurposing approach in DLBCL, and point to dasatinib as an attractive strategy for further clinical development in lymphomas.

DOI: 10.1073/pnas.1905239116
PubMed: 31383760
PubMed Central: PMC6708382

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000216
to stream Main, to step Curation: 000216

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Repurposing dasatinib for diffuse large B cell lymphoma.</title>
<author><name sortKey="Scuoppo, Claudio" sort="Scuoppo, Claudio" uniqKey="Scuoppo C" first="Claudio" last="Scuoppo">Claudio Scuoppo</name>
<affiliation wicri:level="4"><nlm:affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032; cs3064@cumc.columbia.edu rd10@cumc.columbia.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Institute for Cancer Genetics, Columbia University, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
<settlement type="city">New York</settlement>
</placeName>
<orgName type="university">Université Columbia</orgName>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Cell Biology, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Pathology and Cell Biology, Columbia University, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Wang, Jiguang" sort="Wang, Jiguang" uniqKey="Wang J" first="Jiguang" last="Wang">Jiguang Wang</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Systems Biology, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Systems Biology, Columbia University, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Persaud, Mirjana" sort="Persaud, Mirjana" uniqKey="Persaud M" first="Mirjana" last="Persaud">Mirjana Persaud</name>
<affiliation wicri:level="2"><nlm:affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Institute for Cancer Genetics, Columbia University, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mittan, Sandeep K" sort="Mittan, Sandeep K" uniqKey="Mittan S" first="Sandeep K" last="Mittan">Sandeep K. Mittan</name>
<affiliation wicri:level="2"><nlm:affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Institute for Cancer Genetics, Columbia University, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Basso, Katia" sort="Basso, Katia" uniqKey="Basso K" first="Katia" last="Basso">Katia Basso</name>
<affiliation wicri:level="2"><nlm:affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Institute for Cancer Genetics, Columbia University, New York</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Cell Biology, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Pathology and Cell Biology, Columbia University, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Pasqualucci, Laura" sort="Pasqualucci, Laura" uniqKey="Pasqualucci L" first="Laura" last="Pasqualucci">Laura Pasqualucci</name>
<affiliation wicri:level="2"><nlm:affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Institute for Cancer Genetics, Columbia University, New York</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Cell Biology, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Pathology and Cell Biology, Columbia University, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Rabadan, Raul" sort="Rabadan, Raul" uniqKey="Rabadan R" first="Raul" last="Rabadan">Raul Rabadan</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Systems Biology, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Systems Biology, Columbia University, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Inghirami, Giorgio" sort="Inghirami, Giorgio" uniqKey="Inghirami G" first="Giorgio" last="Inghirami">Giorgio Inghirami</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Grandori, Carla" sort="Grandori, Carla" uniqKey="Grandori C" first="Carla" last="Grandori">Carla Grandori</name>
<affiliation wicri:level="2"><nlm:affiliation>Cure First and SEngine Precision Medicine, Seattle, WA 98109.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Washington (État)</region>
</placeName>
<wicri:cityArea>Cure First and SEngine Precision Medicine, Seattle</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Bosch, Francesc" sort="Bosch, Francesc" uniqKey="Bosch F" first="Francesc" last="Bosch">Francesc Bosch</name>
<affiliation wicri:level="2"><nlm:affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Institute for Cancer Genetics, Columbia University, New York</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Hematology and Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, 08035 Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Hematology and Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, 08035 Barcelona</wicri:regionArea>
<placeName><region nuts="2" type="communauté">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dalla Favera, Riccardo" sort="Dalla Favera, Riccardo" uniqKey="Dalla Favera R" first="Riccardo" last="Dalla-Favera">Riccardo Dalla-Favera</name>
<affiliation wicri:level="4"><nlm:affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032; cs3064@cumc.columbia.edu rd10@cumc.columbia.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Institute for Cancer Genetics, Columbia University, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
<settlement type="city">New York</settlement>
</placeName>
<orgName type="university">Université Columbia</orgName>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Cell Biology, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Pathology and Cell Biology, Columbia University, New York</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Genetics and Development, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Genetics and Development, Columbia University, New York</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Microbiology and Immunology, Columbia University, New York</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:31383760</idno>
<idno type="pmid">31383760</idno>
<idno type="doi">10.1073/pnas.1905239116</idno>
<idno type="pmc">PMC6708382</idno>
<idno type="wicri:Area/Main/Corpus">000216</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000216</idno>
<idno type="wicri:Area/Main/Curation">000216</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000216</idno>
<idno type="wicri:Area/Main/Exploration">000216</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Repurposing dasatinib for diffuse large B cell lymphoma.</title>
<author><name sortKey="Scuoppo, Claudio" sort="Scuoppo, Claudio" uniqKey="Scuoppo C" first="Claudio" last="Scuoppo">Claudio Scuoppo</name>
<affiliation wicri:level="4"><nlm:affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032; cs3064@cumc.columbia.edu rd10@cumc.columbia.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Institute for Cancer Genetics, Columbia University, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
<settlement type="city">New York</settlement>
</placeName>
<orgName type="university">Université Columbia</orgName>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Cell Biology, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Pathology and Cell Biology, Columbia University, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Wang, Jiguang" sort="Wang, Jiguang" uniqKey="Wang J" first="Jiguang" last="Wang">Jiguang Wang</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Systems Biology, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Systems Biology, Columbia University, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Persaud, Mirjana" sort="Persaud, Mirjana" uniqKey="Persaud M" first="Mirjana" last="Persaud">Mirjana Persaud</name>
<affiliation wicri:level="2"><nlm:affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Institute for Cancer Genetics, Columbia University, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mittan, Sandeep K" sort="Mittan, Sandeep K" uniqKey="Mittan S" first="Sandeep K" last="Mittan">Sandeep K. Mittan</name>
<affiliation wicri:level="2"><nlm:affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Institute for Cancer Genetics, Columbia University, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Basso, Katia" sort="Basso, Katia" uniqKey="Basso K" first="Katia" last="Basso">Katia Basso</name>
<affiliation wicri:level="2"><nlm:affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Institute for Cancer Genetics, Columbia University, New York</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Cell Biology, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Pathology and Cell Biology, Columbia University, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Pasqualucci, Laura" sort="Pasqualucci, Laura" uniqKey="Pasqualucci L" first="Laura" last="Pasqualucci">Laura Pasqualucci</name>
<affiliation wicri:level="2"><nlm:affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Institute for Cancer Genetics, Columbia University, New York</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Cell Biology, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Pathology and Cell Biology, Columbia University, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Rabadan, Raul" sort="Rabadan, Raul" uniqKey="Rabadan R" first="Raul" last="Rabadan">Raul Rabadan</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Systems Biology, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Systems Biology, Columbia University, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Inghirami, Giorgio" sort="Inghirami, Giorgio" uniqKey="Inghirami G" first="Giorgio" last="Inghirami">Giorgio Inghirami</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Grandori, Carla" sort="Grandori, Carla" uniqKey="Grandori C" first="Carla" last="Grandori">Carla Grandori</name>
<affiliation wicri:level="2"><nlm:affiliation>Cure First and SEngine Precision Medicine, Seattle, WA 98109.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Washington (État)</region>
</placeName>
<wicri:cityArea>Cure First and SEngine Precision Medicine, Seattle</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Bosch, Francesc" sort="Bosch, Francesc" uniqKey="Bosch F" first="Francesc" last="Bosch">Francesc Bosch</name>
<affiliation wicri:level="2"><nlm:affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Institute for Cancer Genetics, Columbia University, New York</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Hematology and Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, 08035 Barcelona, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Hematology and Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, 08035 Barcelona</wicri:regionArea>
<placeName><region nuts="2" type="communauté">Catalogne</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dalla Favera, Riccardo" sort="Dalla Favera, Riccardo" uniqKey="Dalla Favera R" first="Riccardo" last="Dalla-Favera">Riccardo Dalla-Favera</name>
<affiliation wicri:level="4"><nlm:affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032; cs3064@cumc.columbia.edu rd10@cumc.columbia.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Institute for Cancer Genetics, Columbia University, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
<settlement type="city">New York</settlement>
</placeName>
<orgName type="university">Université Columbia</orgName>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Cell Biology, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Pathology and Cell Biology, Columbia University, New York</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Genetics and Development, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Genetics and Development, Columbia University, New York</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Microbiology and Immunology, Columbia University, New York, NY 10032.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Microbiology and Immunology, Columbia University, New York</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Proceedings of the National Academy of Sciences of the United States of America</title>
<idno type="eISSN">1091-6490</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term>
<term>Cell Line, Tumor (MeSH)</term>
<term>Dasatinib (pharmacology)</term>
<term>Drug Resistance, Neoplasm (drug effects)</term>
<term>Humans (MeSH)</term>
<term>Lymphoma, Large B-Cell, Diffuse (drug therapy)</term>
<term>Lymphoma, Large B-Cell, Diffuse (metabolism)</term>
<term>Lymphoma, Large B-Cell, Diffuse (pathology)</term>
<term>Mechanistic Target of Rapamycin Complex 2 (metabolism)</term>
<term>Mice (MeSH)</term>
<term>PTEN Phosphohydrolase (metabolism)</term>
<term>Phosphatidylinositol 3-Kinases (metabolism)</term>
<term>Proof of Concept Study (MeSH)</term>
<term>Pyrazoles (pharmacology)</term>
<term>Pyrimidines (pharmacology)</term>
<term>Xenograft Model Antitumor Assays (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term>
<term>Complexe-2 cible mécanistique de la rapamycine (métabolisme)</term>
<term>Dasatinib (pharmacologie)</term>
<term>Humains (MeSH)</term>
<term>Lignée cellulaire tumorale (MeSH)</term>
<term>Lymphome B diffus à grandes cellules (anatomopathologie)</term>
<term>Lymphome B diffus à grandes cellules (métabolisme)</term>
<term>Lymphome B diffus à grandes cellules (traitement médicamenteux)</term>
<term>Phosphatidylinositol 3-kinases (métabolisme)</term>
<term>Phosphohydrolase PTEN (métabolisme)</term>
<term>Pyrazoles (pharmacologie)</term>
<term>Pyrimidines (pharmacologie)</term>
<term>Résistance aux médicaments antinéoplasiques (effets des médicaments et des substances chimiques)</term>
<term>Souris (MeSH)</term>
<term>Tests d'activité antitumorale sur modèle de xénogreffe (MeSH)</term>
<term>Étude de validation de principe (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Mechanistic Target of Rapamycin Complex 2</term>
<term>PTEN Phosphohydrolase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Dasatinib</term>
<term>Pyrazoles</term>
<term>Pyrimidines</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Lymphome B diffus à grandes cellules</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Drug Resistance, Neoplasm</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphoma, Large B-Cell, Diffuse</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Résistance aux médicaments antinéoplasiques</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lymphoma, Large B-Cell, Diffuse</term>
<term>Phosphatidylinositol 3-Kinases</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Complexe-2 cible mécanistique de la rapamycine</term>
<term>Lymphome B diffus à grandes cellules</term>
<term>Phosphatidylinositol 3-kinases</term>
<term>Phosphohydrolase PTEN</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lymphoma, Large B-Cell, Diffuse</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Dasatinib</term>
<term>Pyrazoles</term>
<term>Pyrimidines</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphome B diffus à grandes cellules</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line, Tumor</term>
<term>Humans</term>
<term>Mice</term>
<term>Proof of Concept Study</term>
<term>Xenograft Model Antitumor Assays</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Lignée cellulaire tumorale</term>
<term>Souris</term>
<term>Tests d'activité antitumorale sur modèle de xénogreffe</term>
<term>Étude de validation de principe</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To repurpose compounds for diffuse large B cell lymphoma (DLBCL), we screened a library of drugs and other targeted compounds approved by the US Food and Drug Administration on 9 cell lines and validated the results on a panel of 32 genetically characterized DLBCL cell lines. Dasatinib, a multikinase inhibitor, was effective against 50% of DLBCL cell lines, as well as against in vivo xenografts. Dasatinib was more broadly active than the Bruton kinase inhibitor ibrutinib and overcame ibrutinib resistance. Tumors exhibiting dasatinib resistance were commonly characterized by activation of the PI3K pathway and loss of PTEN expression as a specific biomarker. PI3K suppression by mTORC2 inhibition synergized with dasatinib and abolished resistance in vitro and in vivo. These results provide a proof of concept for the repurposing approach in DLBCL, and point to dasatinib as an attractive strategy for further clinical development in lymphomas.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31383760</PMID>
<DateCompleted><Year>2020</Year>
<Month>03</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>06</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>116</Volume>
<Issue>34</Issue>
<PubDate><Year>2019</Year>
<Month>08</Month>
<Day>20</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation>
</Journal>
<ArticleTitle>Repurposing dasatinib for diffuse large B cell lymphoma.</ArticleTitle>
<Pagination><MedlinePgn>16981-16986</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1905239116</ELocationID>
<Abstract><AbstractText>To repurpose compounds for diffuse large B cell lymphoma (DLBCL), we screened a library of drugs and other targeted compounds approved by the US Food and Drug Administration on 9 cell lines and validated the results on a panel of 32 genetically characterized DLBCL cell lines. Dasatinib, a multikinase inhibitor, was effective against 50% of DLBCL cell lines, as well as against in vivo xenografts. Dasatinib was more broadly active than the Bruton kinase inhibitor ibrutinib and overcame ibrutinib resistance. Tumors exhibiting dasatinib resistance were commonly characterized by activation of the PI3K pathway and loss of PTEN expression as a specific biomarker. PI3K suppression by mTORC2 inhibition synergized with dasatinib and abolished resistance in vitro and in vivo. These results provide a proof of concept for the repurposing approach in DLBCL, and point to dasatinib as an attractive strategy for further clinical development in lymphomas.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scuoppo</LastName>
<ForeName>Claudio</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032; cs3064@cumc.columbia.edu rd10@cumc.columbia.edu.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University, New York, NY 10032.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Jiguang</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Systems Biology, Columbia University, New York, NY 10032.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Persaud</LastName>
<ForeName>Mirjana</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mittan</LastName>
<ForeName>Sandeep K</ForeName>
<Initials>SK</Initials>
<AffiliationInfo><Affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Basso</LastName>
<ForeName>Katia</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University, New York, NY 10032.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pasqualucci</LastName>
<ForeName>Laura</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University, New York, NY 10032.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rabadan</LastName>
<ForeName>Raul</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Department of Systems Biology, Columbia University, New York, NY 10032.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Inghirami</LastName>
<ForeName>Giorgio</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Grandori</LastName>
<ForeName>Carla</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Cure First and SEngine Precision Medicine, Seattle, WA 98109.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bosch</LastName>
<ForeName>Francesc</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Hematology and Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, 08035 Barcelona, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dalla-Favera</LastName>
<ForeName>Riccardo</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Institute for Cancer Genetics, Columbia University, New York, NY 10032; cs3064@cumc.columbia.edu rd10@cumc.columbia.edu.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University, New York, NY 10032.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Genetics and Development, Columbia University, New York, NY 10032.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Columbia University, New York, NY 10032.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P50 CA192937</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>U54 CA193313</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P30 CA013696</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>U01 CA217883</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R35 CA210105</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>T34 GM007823</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2019</Year>
<Month>08</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C551803">PCI 32765</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D000076225">Mechanistic Target of Rapamycin Complex 2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.1.3.67</RegistryNumber>
<NameOfSubstance UI="D051059">PTEN Phosphohydrolase</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.1.3.67</RegistryNumber>
<NameOfSubstance UI="C494929">PTEN protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>RBZ1571X5H</RegistryNumber>
<NameOfSubstance UI="D000069439">Dasatinib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000069439" MajorTopicYN="N">Dasatinib</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016403" MajorTopicYN="Y">Lymphoma, Large B-Cell, Diffuse</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000076225" MajorTopicYN="N">Mechanistic Target of Rapamycin Complex 2</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051059" MajorTopicYN="N">PTEN Phosphohydrolase</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000075082" MajorTopicYN="N">Proof of Concept Study</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">DLBCL</Keyword>
<Keyword MajorTopicYN="Y">PTEN</Keyword>
<Keyword MajorTopicYN="Y">dasatinib</Keyword>
</KeywordList>
<CoiStatement>Conflict of interest statement: G.I. and reviewer Margaret Shipp are coauthors on a 2016 paper.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>8</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>3</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>8</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">31383760</ArticleId>
<ArticleId IdType="pii">1905239116</ArticleId>
<ArticleId IdType="doi">10.1073/pnas.1905239116</ArticleId>
<ArticleId IdType="pmc">PMC6708382</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Nature. 2000 Feb 3;403(6769):503-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10676951</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2003 Mar;4(3):274-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12563261</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2004 Jul 16;305(5682):399-401</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15256671</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16870-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17077147</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Leukemia. 2008 Sep;22(9):1755-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18596745</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Cancer. 2009 Jan;9(1):28-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19104514</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2009 Oct 30;139(3):573-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19879843</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2010 Jan 7;463(7277):88-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20054396</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20615965</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Investig Drugs. 2010 Nov;19(11):1355-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20846000</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2011 Mar 31;117(13):3585-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21263154</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cancer Ther. 2011 Aug;10(8):1394-406</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21673091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Investig Drugs. 2012 Jan;21(1):15-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22112004</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2012 Mar 28;483(7391):603-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22460905</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Leukemia. 2013 Mar;27(3):586-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23090679</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Opin Drug Saf. 2013 Mar;12(2):177-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23252795</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Transl Med. 2012 Nov 15;1(1):29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23369283</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2013 Jun 10;23(6):826-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23764004</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12420-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23840064</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2014 Jun 12;370(24):2286-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24869598</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2015 Feb 26;125(9):1444-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25499760</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Cancer Ther. 2015 Feb;14(2):395-406</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25519700</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Chemother Pharmacol. 2015 May;75(5):907-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25724156</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2017 Jan 9;31(1):64-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28073005</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Cell. 2017 Jun 12;31(6):833-843.e5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28552327</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Oncol. 2017 Sep 1;28(9):2047-2049</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28911078</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2018 Feb 22;131(8):877-887</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29191916</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2018 May 24;131(21):2345-2356</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29567799</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Oncol. 2018 Jun 1;36(16):1603-1610</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29672223</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2018 May;24(5):679-690</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29713087</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2019 Jan 3;133(1):70-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30322870</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Haematol. 2019 Mar;184(5):744-752</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30520026</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol Methods. 1993 Mar 15;160(1):81-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7680699</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 1994 Apr 15;13(8):1911-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8168489</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioorg Med Chem. 1998 Aug;6(8):1219-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9784863</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Espagne</li>
<li>États-Unis</li>
</country>
<region><li>Catalogne</li>
<li>Washington (État)</li>
<li>État de New York</li>
</region>
<settlement><li>New York</li>
</settlement>
<orgName><li>Université Columbia</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="État de New York"><name sortKey="Scuoppo, Claudio" sort="Scuoppo, Claudio" uniqKey="Scuoppo C" first="Claudio" last="Scuoppo">Claudio Scuoppo</name>
</region>
<name sortKey="Basso, Katia" sort="Basso, Katia" uniqKey="Basso K" first="Katia" last="Basso">Katia Basso</name>
<name sortKey="Basso, Katia" sort="Basso, Katia" uniqKey="Basso K" first="Katia" last="Basso">Katia Basso</name>
<name sortKey="Bosch, Francesc" sort="Bosch, Francesc" uniqKey="Bosch F" first="Francesc" last="Bosch">Francesc Bosch</name>
<name sortKey="Dalla Favera, Riccardo" sort="Dalla Favera, Riccardo" uniqKey="Dalla Favera R" first="Riccardo" last="Dalla-Favera">Riccardo Dalla-Favera</name>
<name sortKey="Dalla Favera, Riccardo" sort="Dalla Favera, Riccardo" uniqKey="Dalla Favera R" first="Riccardo" last="Dalla-Favera">Riccardo Dalla-Favera</name>
<name sortKey="Dalla Favera, Riccardo" sort="Dalla Favera, Riccardo" uniqKey="Dalla Favera R" first="Riccardo" last="Dalla-Favera">Riccardo Dalla-Favera</name>
<name sortKey="Dalla Favera, Riccardo" sort="Dalla Favera, Riccardo" uniqKey="Dalla Favera R" first="Riccardo" last="Dalla-Favera">Riccardo Dalla-Favera</name>
<name sortKey="Grandori, Carla" sort="Grandori, Carla" uniqKey="Grandori C" first="Carla" last="Grandori">Carla Grandori</name>
<name sortKey="Inghirami, Giorgio" sort="Inghirami, Giorgio" uniqKey="Inghirami G" first="Giorgio" last="Inghirami">Giorgio Inghirami</name>
<name sortKey="Mittan, Sandeep K" sort="Mittan, Sandeep K" uniqKey="Mittan S" first="Sandeep K" last="Mittan">Sandeep K. Mittan</name>
<name sortKey="Pasqualucci, Laura" sort="Pasqualucci, Laura" uniqKey="Pasqualucci L" first="Laura" last="Pasqualucci">Laura Pasqualucci</name>
<name sortKey="Pasqualucci, Laura" sort="Pasqualucci, Laura" uniqKey="Pasqualucci L" first="Laura" last="Pasqualucci">Laura Pasqualucci</name>
<name sortKey="Persaud, Mirjana" sort="Persaud, Mirjana" uniqKey="Persaud M" first="Mirjana" last="Persaud">Mirjana Persaud</name>
<name sortKey="Rabadan, Raul" sort="Rabadan, Raul" uniqKey="Rabadan R" first="Raul" last="Rabadan">Raul Rabadan</name>
<name sortKey="Scuoppo, Claudio" sort="Scuoppo, Claudio" uniqKey="Scuoppo C" first="Claudio" last="Scuoppo">Claudio Scuoppo</name>
<name sortKey="Wang, Jiguang" sort="Wang, Jiguang" uniqKey="Wang J" first="Jiguang" last="Wang">Jiguang Wang</name>
</country>
<country name="Espagne"><region name="Catalogne"><name sortKey="Bosch, Francesc" sort="Bosch, Francesc" uniqKey="Bosch F" first="Francesc" last="Bosch">Francesc Bosch</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000245 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000245 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:31383760
   |texte=   Repurposing dasatinib for diffuse large B cell lymphoma.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:31383760" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020

	Serveur d'exploration sur la rapamycine et les champignons
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la rapamycine et les champignons

Repurposing dasatinib for diffuse large B cell lymphoma.

Repurposing dasatinib for diffuse large B cell lymphoma.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki